Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma

on behalf of the Head and Neck Cancer SPORE HIV supplement consortium

Research output: Contribution to journalArticle

Abstract

Background: We examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer). Methods: Tissue microarrays (TMAs) were constructed using tumors from 41 disease site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-negative head and neck cancer controls. Expression of tumor biomarkers was assessed by immunohistochemistry (IHC) and correlations examined with clinical variables. Results: Expression levels of the studied oncogenic and inflammatory tumor biomarkers were not differentially regulated by HIV status. Among patients with HIV-positive head and neck cancer, laryngeal disease site (P =.003) and Clavien-Dindo classification IV (CD4) counts <200 cells/μL (P =.01) were associated with poor prognosis. Multivariate analysis showed that p16 positivity was associated with improved overall survival (OS; P <.001) whereas increased expression of transforming growth factor-beta (TGF-β) was associated with poor clinical outcome (P =.001). Conclusion: Disease site has significant effect on the expression of biomarkers. Expression of tumor TGF-β could be a valuable addition to the conventional risk stratification equation for improving head and neck cancer disease management strategies.

Original languageEnglish (US)
Pages (from-to)2433-2443
Number of pages11
JournalHead and Neck
Volume39
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Virus Diseases
Head and Neck Neoplasms
Biomarkers
HIV
Tumor Biomarkers
Transforming Growth Factor beta
Laryngeal Diseases
Carcinoma, squamous cell of head and neck
CD4 Lymphocyte Count
Disease Management
Neoplasms
Multivariate Analysis
Immunohistochemistry
Survival

Keywords

  • biomarkers
  • head and neck cancer
  • human immunodeficiency virus (HIV)
  • prognosis
  • survival

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. / on behalf of the Head and Neck Cancer SPORE HIV supplement consortium.

In: Head and Neck, Vol. 39, No. 12, 01.12.2017, p. 2433-2443.

Research output: Contribution to journalArticle

on behalf of the Head and Neck Cancer SPORE HIV supplement consortium. / Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. In: Head and Neck. 2017 ; Vol. 39, No. 12. pp. 2433-2443.
@article{3a5decfb89384d84b74f3f0529fec08e,
title = "Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma",
abstract = "Background: We examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer). Methods: Tissue microarrays (TMAs) were constructed using tumors from 41 disease site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-negative head and neck cancer controls. Expression of tumor biomarkers was assessed by immunohistochemistry (IHC) and correlations examined with clinical variables. Results: Expression levels of the studied oncogenic and inflammatory tumor biomarkers were not differentially regulated by HIV status. Among patients with HIV-positive head and neck cancer, laryngeal disease site (P =.003) and Clavien-Dindo classification IV (CD4) counts <200 cells/μL (P =.01) were associated with poor prognosis. Multivariate analysis showed that p16 positivity was associated with improved overall survival (OS; P <.001) whereas increased expression of transforming growth factor-beta (TGF-β) was associated with poor clinical outcome (P =.001). Conclusion: Disease site has significant effect on the expression of biomarkers. Expression of tumor TGF-β could be a valuable addition to the conventional risk stratification equation for improving head and neck cancer disease management strategies.",
keywords = "biomarkers, head and neck cancer, human immunodeficiency virus (HIV), prognosis, survival",
author = "{on behalf of the Head and Neck Cancer SPORE HIV supplement consortium} and Hongzheng Zhang and Sungjin Kim and Zhengjia Chen and Sreenivas Nannapaneni and Chen, {Amy Y.} and Moore, {Charles E.} and Gabriel Sica and Marina Mosunjac and Nguyen, {Minh Ly T.} and Gypsyamber D'Souza and Carey, {Thomas E.} and Peterson, {Lisa A.} and McHugh, {Jonathan B.} and Martin Graham and Komarck, {Christine M.} and Wolf, {Gregory T.} and Walline, {Heather M.} and Emily Bellile and James Riddell and Pai, {Sara I.} and David Sidransky and Westra, {William H.} and William, {William N.} and Lee, {J. Jack} and El-Naggar, {Adel K.} and Ferris, {Robert L.} and Raja Seethala and Grandis, {Jennifer R.} and Chen, {Zhuo Georgia} and Saba, {Nabil F.} and Shin, {Dong M.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/hed.24911",
language = "English (US)",
volume = "39",
pages = "2433--2443",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma

AU - on behalf of the Head and Neck Cancer SPORE HIV supplement consortium

AU - Zhang, Hongzheng

AU - Kim, Sungjin

AU - Chen, Zhengjia

AU - Nannapaneni, Sreenivas

AU - Chen, Amy Y.

AU - Moore, Charles E.

AU - Sica, Gabriel

AU - Mosunjac, Marina

AU - Nguyen, Minh Ly T.

AU - D'Souza, Gypsyamber

AU - Carey, Thomas E.

AU - Peterson, Lisa A.

AU - McHugh, Jonathan B.

AU - Graham, Martin

AU - Komarck, Christine M.

AU - Wolf, Gregory T.

AU - Walline, Heather M.

AU - Bellile, Emily

AU - Riddell, James

AU - Pai, Sara I.

AU - Sidransky, David

AU - Westra, William H.

AU - William, William N.

AU - Lee, J. Jack

AU - El-Naggar, Adel K.

AU - Ferris, Robert L.

AU - Seethala, Raja

AU - Grandis, Jennifer R.

AU - Chen, Zhuo Georgia

AU - Saba, Nabil F.

AU - Shin, Dong M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: We examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer). Methods: Tissue microarrays (TMAs) were constructed using tumors from 41 disease site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-negative head and neck cancer controls. Expression of tumor biomarkers was assessed by immunohistochemistry (IHC) and correlations examined with clinical variables. Results: Expression levels of the studied oncogenic and inflammatory tumor biomarkers were not differentially regulated by HIV status. Among patients with HIV-positive head and neck cancer, laryngeal disease site (P =.003) and Clavien-Dindo classification IV (CD4) counts <200 cells/μL (P =.01) were associated with poor prognosis. Multivariate analysis showed that p16 positivity was associated with improved overall survival (OS; P <.001) whereas increased expression of transforming growth factor-beta (TGF-β) was associated with poor clinical outcome (P =.001). Conclusion: Disease site has significant effect on the expression of biomarkers. Expression of tumor TGF-β could be a valuable addition to the conventional risk stratification equation for improving head and neck cancer disease management strategies.

AB - Background: We examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer). Methods: Tissue microarrays (TMAs) were constructed using tumors from 41 disease site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-negative head and neck cancer controls. Expression of tumor biomarkers was assessed by immunohistochemistry (IHC) and correlations examined with clinical variables. Results: Expression levels of the studied oncogenic and inflammatory tumor biomarkers were not differentially regulated by HIV status. Among patients with HIV-positive head and neck cancer, laryngeal disease site (P =.003) and Clavien-Dindo classification IV (CD4) counts <200 cells/μL (P =.01) were associated with poor prognosis. Multivariate analysis showed that p16 positivity was associated with improved overall survival (OS; P <.001) whereas increased expression of transforming growth factor-beta (TGF-β) was associated with poor clinical outcome (P =.001). Conclusion: Disease site has significant effect on the expression of biomarkers. Expression of tumor TGF-β could be a valuable addition to the conventional risk stratification equation for improving head and neck cancer disease management strategies.

KW - biomarkers

KW - head and neck cancer

KW - human immunodeficiency virus (HIV)

KW - prognosis

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85030628234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030628234&partnerID=8YFLogxK

U2 - 10.1002/hed.24911

DO - 10.1002/hed.24911

M3 - Article

C2 - 28945296

AN - SCOPUS:85030628234

VL - 39

SP - 2433

EP - 2443

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

IS - 12

ER -